Effects of Neuralli® MP on Self-Defined Outcomes in Adults With Autistic Traits

Launched by MACKAY MEMORIAL HOSPITAL · Jul 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a product called Neuralli® MP to see if it can help adults with autistic traits improve outcomes that matter most to them personally. The goal is to understand whether Neuralli® MP can make a positive difference in areas that participants define for themselves, such as daily functioning or quality of life.

Adults between 18 and 50 years old who show signs of autism and want to work but have not yet been able to join a sheltered workshop at the Kanner Foundation may be able to take part. Participants, along with their caregivers and staff at the institution, need to be willing to answer questions and participate in interviews. People who have recently taken antibiotics or probiotics, have dairy allergies, certain immune problems, or specific gut conditions won’t be eligible. Those who join will be asked to participate in questionnaires and interviews to help researchers learn about their experiences with Neuralli® MP. The study is not yet recruiting, but it aims to gather important information about how this treatment might support adults with autistic traits in their daily lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants aged between 18 and 50 who exhibit autistic traits
• • Those who have the willingness and ability to work but have not yet been able to enter a sheltered workshop at the Kanner Foundation
• • The subjects, primary caregivers and institution staff are willing to participate in the study, and the primary caregivers and institution staff are willing to fill out the questionnaire and accept the interview
• Exclusion Criteria:
• • Those who have taken antibiotics or probiotic products in powder, capsule or tablet form within the past month are excluded.
• • Participants currently receiving antibiotic treatment are also excluded.
• • Individuals with a known allergy to dairy products.
• • Individuals with immunodeficiency or compromised immune function.
• • Individuals diagnosed with small intestinal bacterial overgrowth (SIBO)
• • Ineligibility determined by PI, e.g. the individual starts any new medication or therapy, especially related to their autism, during this time.